Sunshine Biopharma, Inc.
SBFM
$1.55
-$0.04-2.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.51% | 44.75% | 61.94% | 109.82% | 193.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.51% | 44.75% | 61.94% | 109.82% | 193.30% |
| Cost of Revenue | 40.92% | 53.64% | 74.29% | 130.87% | 216.08% |
| Gross Profit | 24.60% | 27.95% | 39.69% | 73.61% | 156.09% |
| SG&A Expenses | 36.67% | 37.17% | -10.70% | -13.47% | -5.05% |
| Depreciation & Amortization | 56.40% | 49.80% | 59.38% | 93.62% | 176.58% |
| Other Operating Expenses | 39.55% | 33.59% | 32.41% | 62.92% | 153.91% |
| Total Operating Expenses | 34.99% | 40.60% | 30.54% | 45.36% | 68.89% |
| Operating Income | -31.79% | -19.82% | 43.27% | 52.22% | 53.33% |
| Income Before Tax | -43.36% | -30.60% | 84.40% | 86.25% | 86.20% |
| Income Tax Expenses | -180.08% | -159.40% | -72.03% | -116.34% | 32.83% |
| Earnings from Continuing Operations | -23.06% | -13.94% | 84.21% | 86.66% | 84.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.06% | -13.94% | 84.21% | 86.66% | 84.98% |
| EBIT | -31.79% | -19.82% | 43.27% | 52.22% | 53.33% |
| EBITDA | -30.86% | -18.86% | 44.78% | 53.59% | 54.74% |
| EPS Basic | 94.13% | 96.17% | 95.85% | 93.62% | 90.71% |
| Normalized Basic EPS | 89.63% | 93.80% | 87.18% | 79.14% | 68.90% |
| EPS Diluted | 94.13% | 96.17% | 95.85% | 93.62% | 90.71% |
| Normalized Diluted EPS | 89.63% | 93.80% | 87.18% | 79.14% | 68.90% |
| Average Basic Shares Outstanding | 805.87% | 7,958.24% | 4,036.48% | 1,958.17% | 2,968.92% |
| Average Diluted Shares Outstanding | 805.87% | 7,958.24% | 4,036.48% | 1,958.17% | 2,968.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |